|
EP2141233B1
(en)
|
2002-11-18 |
2016-10-19 |
Roche Innovation Center Copenhagen A/S |
Antisense design
|
|
DK2379084T3
(en)
|
2008-10-15 |
2018-01-22 |
Ionis Pharmaceuticals Inc |
MODULATION OF FACTOR 11 EXPRESSION
|
|
SG171914A1
(en)
|
2008-12-02 |
2011-07-28 |
Chiralgen Ltd |
Method for the synthesis of phosphorus atom modified nucleic acids
|
|
US9744183B2
(en)
|
2009-07-06 |
2017-08-29 |
Wave Life Sciences Ltd. |
Nucleic acid prodrugs and methods of use thereof
|
|
US11083444B2
(en)
|
2010-03-11 |
2021-08-10 |
Globus Medical, Inc. |
Tissue retractor and methods of use
|
|
DK2620428T3
(da)
|
2010-09-24 |
2019-07-01 |
Wave Life Sciences Ltd |
Asymmetrisk hjælpegruppe
|
|
AU2011329777B2
(en)
|
2010-11-17 |
2016-06-09 |
Ionis Pharmaceuticals, Inc. |
Modulation of alpha synuclein expression
|
|
RU2014105311A
(ru)
|
2011-07-19 |
2015-08-27 |
Уэйв Лайф Сайенсес Пте. Лтд. |
Способы синтеза функционализованных нуклеиновых кислот
|
|
EP2756080B1
(en)
|
2011-09-14 |
2019-02-20 |
Translate Bio MA, Inc. |
Multimeric oligonucleotide compounds
|
|
WO2013173599A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating hemoglobin gene family expression
|
|
EA201492116A1
(ru)
|
2012-05-16 |
2015-05-29 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии mecp2
|
|
AU2013262656A1
(en)
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating UTRN expression
|
|
AU2013262649A1
(en)
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating smn gene family expression
|
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
|
EP2850182A4
(en)
|
2012-05-16 |
2016-01-20 |
Rana Therapeutics Inc |
COMPOSITIONS AND METHODS FOR MODULATING ATP2A2 GENE EXPRESSION
|
|
KR102712879B1
(ko)
|
2012-07-13 |
2024-10-04 |
웨이브 라이프 사이언시스 리미티드 |
키랄 제어
|
|
PT2872485T
(pt)
|
2012-07-13 |
2021-03-05 |
Wave Life Sciences Ltd |
Grupo auxiliar assimétrico
|
|
CA2884608C
(en)
|
2012-09-14 |
2025-05-20 |
Translate Bio Ma, Inc. |
MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS
|
|
JP6452614B2
(ja)
|
2012-11-15 |
2019-01-16 |
ロシュ イノベーション センター コペンハーゲン エーエス |
オリゴヌクレオチドコンジュゲート
|
|
EP2951305B1
(en)
*
|
2013-01-30 |
2018-08-15 |
F.Hoffmann-La Roche Ag |
Lna oligonucleotide carbohydrate conjugates
|
|
NZ630890A
(en)
|
2013-05-01 |
2017-09-29 |
Regulus Therapeutics Inc |
Microrna compounds and methods for modulating mir-122
|
|
PL2992098T3
(pl)
|
2013-05-01 |
2019-09-30 |
Ionis Pharmaceuticals, Inc. |
Kompozycje i sposoby modulowania ekspresji hbv i ttr
|
|
TWI680767B
(zh)
|
2013-05-01 |
2020-01-01 |
美商雷格勒斯治療公司 |
用於增強的細胞攝取之化合物及方法
|
|
US9943604B2
(en)
|
2013-09-20 |
2018-04-17 |
Ionis Pharmaceuticals, Inc. |
Targeted therapeutic nucleosides and their use
|
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
|
US9994846B2
(en)
|
2013-10-25 |
2018-06-12 |
Regulus Therapeutics Inc. |
MicroRNA compounds and methods for modulating miR-21 activity
|
|
JPWO2015108047A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
|
|
JPWO2015108048A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
|
|
PT3094728T
(pt)
|
2014-01-16 |
2022-05-19 |
Wave Life Sciences Ltd |
Desenho quiral
|
|
US10358643B2
(en)
|
2014-01-30 |
2019-07-23 |
Hoffmann-La Roche, Inc. |
Poly oligomer compound with biocleavable conjugates
|
|
EP3119888B1
(en)
|
2014-03-19 |
2021-07-28 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating ataxin 2 expression
|
|
US10006027B2
(en)
|
2014-03-19 |
2018-06-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating Ataxin 2 expression
|
|
WO2015153800A2
(en)
|
2014-04-01 |
2015-10-08 |
Isis Pharmaceuticals, Inc. |
Compositions for modulating sod-1 expression
|
|
KR102369736B1
(ko)
|
2014-05-01 |
2022-03-02 |
아이오니스 파마수티컬즈, 인코포레이티드 |
보체 인자 b 발현을 조절하기 위한 조성물 및 방법
|
|
ES2812099T3
(es)
|
2014-05-01 |
2021-03-16 |
Ionis Pharmaceuticals Inc |
Composiciones y métodos para modular la expresión del receptor de la hormona del crecimiento
|
|
KR102366078B1
(ko)
|
2014-05-01 |
2022-02-21 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Pkk 발현을 조절하는 조성물 및 방법
|
|
KR102356388B1
(ko)
|
2014-05-01 |
2022-01-26 |
아이오니스 파마수티컬즈, 인코포레이티드 |
안지오포이에틴-유사 3 발현을 조절하기 위한 조성물 및 방법
|
|
GB201408623D0
(en)
|
2014-05-15 |
2014-07-02 |
Santaris Pharma As |
Oligomers and oligomer conjugates
|
|
AU2015301057A1
(en)
|
2014-08-07 |
2017-01-19 |
Regulus Therapeutics Inc. |
Targeting micrornas for metabolic disorders
|
|
WO2016040748A1
(en)
|
2014-09-12 |
2016-03-17 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for detection of smn protein in a subject and treatment of a subject
|
|
MX2017004039A
(es)
|
2014-10-10 |
2017-07-24 |
Hoffmann La Roche |
Fosforamiditas de n-acetilgalactosamina (galnac), conjugados de acido nucleico de las mismas y su uso.
|
|
MX2017006140A
(es)
*
|
2014-11-10 |
2017-11-16 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Composiciones de accion prolongada de combinacion y métodos para hepatitis c.
|
|
EP3234131B1
(en)
|
2014-12-16 |
2020-04-22 |
Roche Innovation Center Copenhagen A/S |
Chiral toxicity screening method
|
|
US20170369872A1
(en)
*
|
2014-12-18 |
2017-12-28 |
Alnylam Pharmaceuticals, Inc. |
Reversir tm compounds
|
|
WO2016112132A1
(en)
|
2015-01-06 |
2016-07-14 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
|
US10538763B2
(en)
|
2015-01-16 |
2020-01-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of DUX4
|
|
WO2016130943A1
(en)
*
|
2015-02-13 |
2016-08-18 |
Rana Therapeutics, Inc. |
Hybrid oligonucleotides and uses thereof
|
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
|
JP6892433B2
(ja)
|
2015-04-03 |
2021-06-23 |
ユニバーシティ・オブ・マサチューセッツＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ |
十分に安定化された非対称ｓｉｒｎａ
|
|
KR102539587B1
(ko)
|
2015-04-03 |
2023-06-01 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Tmprss6 발현을 조절하기 위한 화합물 및 방법들
|
|
SI3277815T1
(sl)
|
2015-04-03 |
2022-01-31 |
University Of Massachusetts |
Ologonukleotidne spojine za zdravljenje preeklampsije in drugih angiogeneznih motenj
|
|
EP3766973A1
(en)
|
2015-04-03 |
2021-01-20 |
University Of Massachusetts |
Oligonucleotide compounds for targeting huntingtin mrna
|
|
WO2016167780A1
(en)
|
2015-04-16 |
2016-10-20 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
|
CA2995110A1
(en)
|
2015-08-14 |
2017-02-23 |
University Of Massachusetts |
Bioactive conjugates for oligonucleotide delivery
|
|
KR20180043819A
(ko)
|
2015-08-24 |
2018-04-30 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
Lna-g 방법
|
|
EP3353305A4
(en)
*
|
2015-09-25 |
2019-09-18 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
KR20180073584A
(ko)
|
2015-10-02 |
2018-07-02 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
올리고뉴클레오타이드 접합 방법
|
|
US20190127733A1
(en)
|
2015-10-09 |
2019-05-02 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|
|
WO2017068087A1
(en)
|
2015-10-22 |
2017-04-27 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide detection method
|
|
EP4119569B1
(en)
*
|
2015-11-06 |
2024-07-31 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds for use in therapy
|
|
MY203086A
(en)
|
2015-11-06 |
2024-06-07 |
Ionis Pharmaceuticals Inc |
Modulating apolipoprotein (a) expression
|
|
CN108350431A
(zh)
|
2015-11-12 |
2018-07-31 |
豪夫迈·罗氏有限公司 |
用于确定候选药物的功效特征的方法
|
|
EP3389670A4
(en)
|
2015-12-04 |
2020-01-08 |
Ionis Pharmaceuticals, Inc. |
METHODS OF TREATING BREAST CANCER
|
|
US20190002887A1
(en)
|
2015-12-31 |
2019-01-03 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing ataxin-2 expression
|
|
EP3400300A4
(en)
|
2016-01-05 |
2019-08-07 |
Ionis Pharmaceuticals, Inc. |
PROCESS FOR REDUCING LRRK2 EXPRESSION
|
|
SG11201806372UA
(en)
*
|
2016-01-29 |
2018-08-30 |
Kyowa Hakko Kirin Co Ltd |
Nucleic acid conjugate
|
|
US10478503B2
(en)
|
2016-01-31 |
2019-11-19 |
University Of Massachusetts |
Branched oligonucleotides
|
|
KR102348425B1
(ko)
|
2016-03-07 |
2022-01-10 |
애로우헤드 파마슈티컬스 인코포레이티드 |
치료용 화합물을 위한 표적화 리간드
|
|
SG11201807854SA
(en)
|
2016-03-14 |
2018-10-30 |
Hoffmann La Roche |
Oligonucleotides for reduction of pd-l1 expression
|
|
WO2017161168A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dyrk1b expression
|
|
EP3429690A4
(en)
|
2016-03-16 |
2019-10-23 |
Ionis Pharmaceuticals, Inc. |
METHOD FOR MODULATING KEAP1
|
|
MA45328A
(fr)
*
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
|
EP3228326A1
(en)
*
|
2016-04-05 |
2017-10-11 |
Silence Therapeutics GmbH |
Nucleic acid linked to a trivalent glycoconjugate
|
|
AU2017248189B2
(en)
*
|
2016-04-08 |
2021-04-29 |
Translate Bio, Inc. |
Multimeric coding nucleic acid and uses thereof
|
|
US11248019B2
(en)
|
2016-04-14 |
2022-02-15 |
Hoffmann-La Roche Inc. |
Trityl-mono-GalNAc compounds and their use
|
|
IL262728B2
(en)
*
|
2016-05-06 |
2023-10-01 |
Astrazeneca Ab |
Oligonucleotides conjugated to the GLP-1 receptor ligand complex and their uses
|
|
WO2017219017A1
(en)
|
2016-06-17 |
2017-12-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of gys1 expression
|
|
MA45496A
(fr)
|
2016-06-17 |
2019-04-24 |
Hoffmann La Roche |
Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
|
|
CN109477103A
(zh)
|
2016-06-22 |
2019-03-15 |
ProQR治疗上市公司Ⅱ |
单链rna-编辑寡核苷酸
|
|
SG10202005885VA
(en)
|
2016-07-01 |
2020-07-29 |
Hoffmann La Roche |
Antisense oligonucleotides for modulating htra1 expression
|
|
CA3033368A1
(en)
|
2016-08-12 |
2018-02-15 |
University Of Massachusetts |
Conjugated oligonucleotides
|
|
KR102501980B1
(ko)
|
2016-09-01 |
2023-02-20 |
프로큐알 테라퓨틱스 Ⅱ 비.브이. |
화학적으로 변형된 단일 가닥 rna-편집 올리고뉴클레오타이드
|
|
SG11201901841TA
(en)
|
2016-09-02 |
2019-03-28 |
Arrowhead Pharmaceuticals Inc |
Targeting ligands
|
|
US11400161B2
(en)
|
2016-10-06 |
2022-08-02 |
Ionis Pharmaceuticals, Inc. |
Method of conjugating oligomeric compounds
|
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
|
US11033570B2
(en)
|
2016-12-02 |
2021-06-15 |
Cold Spring Harbor Laboratory |
Modulation of Lnc05 expression
|
|
EP3568480A1
(en)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb2 expression
|
|
EP3568481A1
(en)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating relb expression
|
|
WO2018130581A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rela expression
|
|
WO2018130583A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb1 expression
|
|
US20190338286A1
(en)
|
2017-01-13 |
2019-11-07 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rel expression
|
|
WO2018164275A1
(ja)
|
2017-03-10 |
2018-09-13 |
国立研究開発法人国立成育医療研究センター |
アンチセンスオリゴヌクレオチドおよび糖原病Ｉａ型予防または治療用組成物
|
|
US11512312B2
(en)
|
2017-03-10 |
2022-11-29 |
The Board Of Regents Of The University Of Texas System |
Treatment of Fuchs' endothelial corneal dystrophy
|
|
SG11201909433XA
(en)
*
|
2017-04-11 |
2019-11-28 |
Arbutus Biopharma Corp |
Targeted compositions
|
|
WO2018215049A1
(en)
*
|
2017-05-23 |
2018-11-29 |
F. Hoffmann-La Roche Ag |
Process for galnac oligonucleotide conjugates
|
|
US11273222B2
(en)
|
2017-05-26 |
2022-03-15 |
National Cerebral And Cardiovascular Center |
Antisense nucleic acid targeting PCSK9
|
|
US20190055564A1
(en)
|
2017-06-01 |
2019-02-21 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for modulating htra1 expression
|
|
US20210198305A1
(en)
*
|
2017-06-02 |
2021-07-01 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
WO2018226788A1
(en)
|
2017-06-07 |
2018-12-13 |
University Of Massachusetts |
Anti-adam33 oligonucleotides and related methods
|
|
EP3642341A4
(en)
|
2017-06-23 |
2021-06-16 |
University Of Massachusetts |
TWO-DAY SELF-RELEASING SIRNA AND RELATED PROCEDURES
|
|
TW201919712A
(zh)
|
2017-08-10 |
2019-06-01 |
法商塞勒尼斯醫療控股公司 |
運送子(cargomers)
|
|
WO2019030313A2
(en)
|
2017-08-11 |
2019-02-14 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF UBE3C EXPRESSION
|
|
AU2018318230B2
(en)
|
2017-08-17 |
2024-10-03 |
Alnylam Pharmaceuticals, Inc. |
Tunable REVERSIRTM compounds
|
|
EP3668984A4
(en)
|
2017-08-18 |
2021-09-08 |
Ionis Pharmaceuticals, Inc. |
MODULATION OF THE NOTCH SIGNALING PATH FOR THE TREATMENT OF RESPIRATORY DISORDERS
|
|
WO2019038228A1
(en)
|
2017-08-22 |
2019-02-28 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION
|
|
WO2019051173A1
(en)
|
2017-09-08 |
2019-03-14 |
Ionis Pharmaceuticals, Inc. |
MODULATORS OF SMAD7 EXPRESSION
|
|
JP2020537518A
(ja)
|
2017-10-12 |
2020-12-24 |
ウェーブ ライフ サイエンシーズ リミテッド |
オリゴヌクレオチド組成物及びその方法
|
|
EP3694995A1
(en)
|
2017-10-13 |
2020-08-19 |
Roche Innovation Center Copenhagen A/S |
Methods for identifying improved stereodefined phosphorothioate oligonucleotide variants of antisense oligonucleotides utilising sub-libraries of partially stereodefined oligonucleotides
|
|
TW202424191A
(zh)
|
2017-10-16 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
用於降低PAPD5及PAPD7 mRNA以治療B型肝炎感染之核酸分子
|
|
CN111386105B
(zh)
|
2017-11-06 |
2023-09-15 |
日东电工株式会社 |
用于递送生物活性分子的膜融合化合物
|
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
|
WO2019105419A1
(zh)
|
2017-12-01 |
2019-06-06 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
CN110944675B9
(zh)
|
2017-12-01 |
2024-08-09 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
WO2019105418A1
(zh)
|
2017-12-01 |
2019-06-06 |
苏州瑞博生物技术有限公司 |
双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途
|
|
WO2019105414A1
(zh)
|
2017-12-01 |
2019-06-06 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
WO2019105437A1
(zh)
|
2017-12-01 |
2019-06-06 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
SG11202005022YA
(en)
|
2017-12-06 |
2020-06-29 |
Avidity Biosciences Inc |
Compositions and methods of treating muscle atrophy and myotonic dystrophy
|
|
EP3724333A2
(en)
|
2017-12-11 |
2020-10-21 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating fndc3b expression
|
|
WO2019115417A2
(en)
|
2017-12-12 |
2019-06-20 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating rb1 expression
|
|
WO2019126641A2
(en)
|
2017-12-21 |
2019-06-27 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
|
WO2019121838A1
(en)
|
2017-12-21 |
2019-06-27 |
F. Hoffmann-La Roche Ag |
Companion diagnostic for htra1 rna antagonists
|
|
JP2021508327A
(ja)
|
2017-12-22 |
2021-03-04 |
ロシュ イノベーション センター コペンハーゲン エーエス |
新規のチオホスホラミダイト
|
|
BR112020012427A8
(pt)
|
2017-12-22 |
2024-04-02 |
Roche Innovation Ct Copenhagen As |
Oligonucleotídeos, sal farmaceuticamente aceitável, conjugado, composição farmacêutica e processo para a fabricação de um oligonucleotídeo
|
|
EP4092117A1
(en)
|
2017-12-22 |
2022-11-23 |
Roche Innovation Center Copenhagen A/S |
Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage
|
|
KR102617947B1
(ko)
*
|
2017-12-29 |
2023-12-27 |
쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 |
접합체와 제조 및 그 용도
|
|
JP2021511022A
(ja)
|
2018-01-10 |
2021-05-06 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Ｐｉａｓ４発現を調節するためのオリゴヌクレオチド
|
|
BR112020012921A2
(pt)
|
2018-01-12 |
2020-12-08 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotídeos antissenso de alfa-sinucleína e usos dos mesmos
|
|
CA3088112A1
(en)
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Antisense oligonucleotides targeting alpha-synuclein and uses thereof
|
|
BR112020014011A2
(pt)
|
2018-01-12 |
2020-12-08 |
Bristol-Myers Squibb Company |
Oligonucleotídeos antissenso dirigidos à alfa-sinucleína e usos dos mesmos
|
|
JP2021510295A
(ja)
|
2018-01-12 |
2021-04-22 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Ｇｓｋ３ｂ発現を調節するためのオリゴヌクレオチド
|
|
CN111902537A
(zh)
|
2018-01-15 |
2020-11-06 |
Ionis制药公司 |
Dnm2表达的调节剂
|
|
JP2021510525A
(ja)
|
2018-01-17 |
2021-04-30 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Ｅｒｃ１発現を調節するためのオリゴヌクレオチド
|
|
US20210095277A1
(en)
|
2018-01-18 |
2021-04-01 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting srebp1
|
|
WO2019145386A1
(en)
|
2018-01-26 |
2019-08-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating csnk1d expression
|
|
CA3085407A1
(en)
*
|
2018-01-26 |
2019-08-01 |
F. Hoffmann-La Roche Ag |
Radiolabelled oligonucleotides and process for their preparation
|
|
CN111868245B
(zh)
|
2018-02-09 |
2024-11-19 |
豪夫迈·罗氏有限公司 |
用于调节tmem106b表达的寡核苷酸
|
|
WO2019169243A1
(en)
|
2018-03-02 |
2019-09-06 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of amyloid-beta precursor protein
|
|
TWI840345B
(zh)
|
2018-03-02 |
2024-05-01 |
美商Ionis製藥公司 |
Irf4表現之調節劑
|
|
EP3763815A4
(en)
|
2018-03-09 |
2021-12-15 |
Daiichi Sankyo Company, Limited |
THERAPEUTIC FOR GLYCOGEN STORAGE DISEASE OF TYPE IA
|
|
WO2019183440A1
(en)
|
2018-03-22 |
2019-09-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating fmr1 expression
|
|
EP3775208A1
(en)
|
2018-04-05 |
2021-02-17 |
F. Hoffmann-La Roche AG |
Use of fubp1 inhibitors for treating hepatitis b virus infection
|
|
KR20200141481A
(ko)
|
2018-04-11 |
2020-12-18 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Ezh2 발현의 조절제
|
|
EP3790991A1
(en)
|
2018-05-07 |
2021-03-17 |
Roche Innovation Center Copenhagen A/S |
Massively parallel discovery methods for oligonucleotide therapeutics
|
|
JP7279081B2
(ja)
|
2018-05-08 |
2023-05-22 |
レグルス セラピューティクス インコーポレイテッド |
Ｍｉｒ－１２２を調節するためのマイクロｒｎａ化合物及び方法
|
|
WO2019215175A1
(en)
|
2018-05-08 |
2019-11-14 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating myh7 expression
|
|
MX2020011911A
(es)
|
2018-05-09 |
2021-01-29 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para reducir de la expresion de atxn3.
|
|
IL277970B2
(en)
|
2018-05-09 |
2025-03-01 |
Ionis Pharmaceuticals Inc |
Oligomeric compounds comprising modified oligonucleotides and conjugated groups for use in the treatment of end-stage renal disease, chronic kidney disease and coronary artery disease
|
|
BR112020022620A2
(pt)
*
|
2018-05-11 |
2021-02-17 |
Alpha Anomeric Sas |
conjugados de oligonucleotídeos que compreendem nucleosídeos de açúcar 7'-5'-alfa-anomérico-bicíclicos
|
|
JP7427608B2
(ja)
|
2018-05-11 |
2024-02-05 |
ウェイブ ライフ サイエンシズ リミテッド |
オリゴヌクレオチド組成物及びその使用方法
|
|
GB201808146D0
(en)
|
2018-05-18 |
2018-07-11 |
Proqr Therapeutics Ii Bv |
Stereospecific Linkages in RNA Editing Oligonucleotides
|
|
EP3802824A1
(en)
|
2018-06-05 |
2021-04-14 |
F. Hoffmann-La Roche AG |
Oligonucleotides for modulating atxn2 expression
|
|
US11833168B2
(en)
|
2018-06-14 |
2023-12-05 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for increasing STMN2 expression
|
|
TWI833770B
(zh)
|
2018-06-27 |
2024-03-01 |
美商Ionis製藥公司 |
用於減少 lrrk2 表現之化合物及方法
|
|
WO2020007772A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting gbp-1
|
|
WO2020007702A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting bcl2l11
|
|
WO2020007700A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting spi1
|
|
RU2768285C1
(ru)
|
2018-07-03 |
2022-03-23 |
Ф. Хоффманн-Ля Рош Аг |
Олигонуклеотиды для модуляции экспрессии тау-белка
|
|
WO2020007889A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting stat1
|
|
WO2020007826A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mbtps1
|
|
WO2020011743A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mafb
|
|
WO2020011653A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting kynu
|
|
WO2020011869A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting tlr2
|
|
WO2020011744A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers5
|
|
WO2020011745A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers6
|
|
KR20210033004A
(ko)
|
2018-07-13 |
2021-03-25 |
에프. 호프만-라 로슈 아게 |
Rtel1의 발현을 조절하기 위한 올리고뉴클레오티드
|
|
US12496311B2
(en)
|
2018-07-17 |
2025-12-16 |
Aronora, Inc. |
Methods for safely reducing thrombopoietin
|
|
AU2019310097A1
(en)
|
2018-07-25 |
2021-02-04 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing ATXN2 expression
|
|
MX2020013270A
(es)
|
2018-07-31 |
2021-02-18 |
Roche Innovation Ct Copenhagen As |
Oligonucleotidos que comprenden enlace internucleosidico de fosforotritioato.
|
|
ES2924362T3
(es)
|
2018-07-31 |
2022-10-06 |
Roche Innovation Ct Copenhagen As |
Oligonucleótidos que comprenden un enlace internucleosídico fosforotritioato
|
|
KR20210093227A
(ko)
|
2018-08-10 |
2021-07-27 |
유니버시티 오브 매사추세츠 |
Snp를 표적화하는 변형된 올리고뉴클레오티드
|
|
US11918600B2
(en)
|
2018-08-21 |
2024-03-05 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof
|
|
JP7627042B2
(ja)
|
2018-08-23 |
2025-02-05 |
ユニバーシティー オブ マサチューセッツ |
Ｏ－メチルリッチ完全安定化オリゴヌクレオチド
|
|
WO2020038973A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting sptlc1
|
|
WO2020038976A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting usp8
|
|
WO2020038968A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Microrna-134 biomarker
|
|
WO2020038971A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting vcan
|
|
JP2021536239A
(ja)
|
2018-08-28 |
2021-12-27 |
ロシュ イノベーション センター コペンハーゲン エーエス |
スプライス調節化合物を使用したネオアンチゲン操作
|
|
EP3620519A1
(en)
|
2018-09-04 |
2020-03-11 |
F. Hoffmann-La Roche AG |
Use of isolated milk extracellular vesicles for delivering oligonucleotides orally
|
|
WO2020051398A1
(en)
*
|
2018-09-06 |
2020-03-12 |
Aptamir Therapeutics, Inc. |
Metabolic benefits of short mir-22 mirna antagomir therapies
|
|
WO2020063198A1
(zh)
|
2018-09-30 |
2020-04-02 |
苏州瑞博生物技术有限公司 |
一种siRNA缀合物及其制备方法和用途
|
|
WO2020089260A1
(en)
|
2018-11-01 |
2020-05-07 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting tia1
|
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
|
US11208650B2
(en)
|
2018-11-15 |
2021-12-28 |
Ionis Pharmaceuticals, Inc. |
Modulators of IRF5 expression
|
|
WO2020106996A1
(en)
|
2018-11-21 |
2020-05-28 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing prion expression
|
|
EP3894559A4
(en)
|
2018-12-03 |
2023-04-05 |
Triplet Therapeutics, Inc. |
METHODS OF TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS RELATED TO MLH3 ACTIVITY
|
|
US20220056455A1
(en)
|
2018-12-20 |
2022-02-24 |
Praxis Precision Medicines, Inc. |
Compositions and methods for the treatment of kcnt1 related disorders
|
|
JP2022514648A
(ja)
|
2018-12-21 |
2022-02-14 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｃａｒｄ９を標的とするアンチセンスオリゴヌクレオチド
|
|
EP3903830A4
(en)
|
2018-12-28 |
2023-04-26 |
Suzhou Ribo Life Science Co., Ltd. |
NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH NUCLEIC ACID, PROCESS FOR THEIR PREPARATION AND ITS USE
|
|
JP2022523467A
(ja)
|
2019-01-18 |
2022-04-25 |
ユニバーシティ・オブ・マサチューセッツ |
動的な薬物動態を修飾するアンカー
|
|
CN113365607A
(zh)
*
|
2019-01-25 |
2021-09-07 |
豪夫迈·罗氏有限公司 |
用于口服药物递送的脂质囊泡
|
|
KR20210122809A
(ko)
|
2019-01-31 |
2021-10-12 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Yap1 발현의 조절인자
|
|
KR20210132681A
(ko)
|
2019-02-20 |
2021-11-04 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
신규 포스포라미디트
|
|
JP2022521510A
(ja)
|
2019-02-20 |
2022-04-08 |
ロシュ イノベーション センター コペンハーゲン エーエス |
ホスホノアセテートギャップマー型オリゴヌクレオチド
|
|
EP3931348B1
(en)
|
2019-02-26 |
2023-08-09 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide formulation method
|
|
BR112021015323A2
(pt)
|
2019-02-27 |
2021-10-05 |
Ionis Pharmaceuticals, Inc. |
Moduladores de expressão de malat1
|
|
JP2022522898A
(ja)
*
|
2019-03-05 |
2022-04-20 |
エフ．ホフマン－ラ ロシュ アーゲー |
分子の細胞内標的化
|
|
TW202536179A
(zh)
|
2019-03-29 |
2025-09-16 |
美商Ionis製藥公司 |
用於調節ube3a-ats之化合物及方法
|
|
EP3947678A1
(en)
|
2019-04-02 |
2022-02-09 |
ProQR Therapeutics II B.V. |
Antisense oligonucleotides for immunotherapy
|
|
CN113906139A
(zh)
|
2019-04-03 |
2022-01-07 |
百时美施贵宝公司 |
Angptl2反义寡核苷酸及其用途
|
|
WO2020201339A1
(en)
|
2019-04-04 |
2020-10-08 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating atxn2 expression
|
|
US11286485B2
(en)
|
2019-04-04 |
2022-03-29 |
Hoffmann-La Roche Inc. |
Oligonucleotides for modulating ATXN2 expression
|
|
AU2020280438B2
(en)
|
2019-05-22 |
2025-03-06 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
|
|
MX2021014206A
(es)
|
2019-05-31 |
2022-01-06 |
Aligos Therapeutics Inc |
Oligonucleotidos gapmer modificados y metodos de uso.
|
|
WO2020245233A1
(en)
|
2019-06-06 |
2020-12-10 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting atxn3
|
|
EP3956450B1
(en)
|
2019-07-26 |
2025-08-13 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating gfap
|
|
CN114466929A
(zh)
*
|
2019-07-30 |
2022-05-10 |
Mpeg La有限责任公司 |
具有增强的生物活性的多聚体寡核苷酸的皮下递送
|
|
CA3149835A1
(en)
|
2019-08-09 |
2021-02-18 |
University Of Massachusetts |
Chemically modified oligonucleotides targeting snps
|
|
TWI896556B
(zh)
|
2019-09-10 |
2025-09-11 |
日商第一三共股份有限公司 |
用於肝臟遞送之GalNAc-寡核苷酸結合物
|
|
US12365894B2
(en)
|
2019-09-16 |
2025-07-22 |
University Of Massachusetts |
Branched lipid conjugates of siRNA for specific tissue delivery
|
|
EP4038187A4
(en)
*
|
2019-10-02 |
2023-06-07 |
Sirnaomics, Inc. |
OLIGONUCLEOTIDES INCLUDING NUCLEOSIDE ANALOGS
|
|
JP2023506954A
(ja)
|
2019-12-19 |
2023-02-20 |
エフ． ホフマン－ラ ロシュ エージー． |
Ｂ型肝炎ウイルス感染を処置するためのｓａｒａｆ阻害剤の使用
|
|
WO2021122921A1
(en)
|
2019-12-19 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Use of cops3 inhibitors for treating hepatitis b virus infection
|
|
WO2021122735A1
(en)
|
2019-12-19 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Use of sept9 inhibitors for treating hepatitis b virus infection
|
|
WO2021122869A1
(en)
|
2019-12-19 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Use of scamp3 inhibitors for treating hepatitis b virus infection
|
|
JP2023506550A
(ja)
|
2019-12-19 |
2023-02-16 |
エフ． ホフマン－ラ ロシュ エージー． |
Ｂ型肝炎ウイルス感染症を処置するためのｓｂｄｓ阻害剤の使用
|
|
WO2021127650A1
(en)
*
|
2019-12-19 |
2021-06-24 |
Entrada Therapeutics, Inc. |
Compositions for delivery of antisense compounds
|
|
EP4077672A1
(en)
|
2019-12-20 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Enhanced oligonucleotides for inhibiting scn9a expression
|
|
WO2021130270A1
(en)
|
2019-12-24 |
2021-07-01 |
F. Hoffmann-La Roche Ag |
Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv
|
|
EP4081639A1
(en)
|
2019-12-24 |
2022-11-02 |
F. Hoffmann-La Roche AG |
Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
|
|
EP4097234A1
(en)
|
2020-01-28 |
2022-12-07 |
Université de Strasbourg |
Antisense oligonucleotide targeting linc00518 for treating melanoma
|
|
WO2021158810A1
(en)
|
2020-02-05 |
2021-08-12 |
Bristol-Myers Squibb Company |
Oligonucleotides for splice modulation of camk2d
|
|
BR112022016238A2
(pt)
|
2020-02-28 |
2022-10-11 |
Ionis Pharmaceuticals Inc |
Compostos e métodos para modular smn2
|
|
CN115176010A
(zh)
|
2020-02-28 |
2022-10-11 |
豪夫迈·罗氏有限公司 |
用于调节cd73外显子7剪接的寡核苷酸
|
|
MX2022010980A
(es)
|
2020-03-04 |
2022-12-02 |
Verve Therapeutics Inc |
Composiciones y metodos para el suministro de arn dirigido.
|
|
JP7788060B2
(ja)
|
2020-03-19 |
2025-12-18 |
アビディティー バイオサイエンシーズ，インク． |
顔面肩甲上腕型筋ジストロフィーを処置するための組成物および方法
|
|
CA3176210A1
(en)
*
|
2020-04-21 |
2021-10-28 |
Nathan Wilson STEBBINS |
Bifunctional molecules and methods of using thereof
|
|
EP4143321A4
(en)
|
2020-05-01 |
2025-02-19 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating atxn1
|
|
WO2021231211A1
(en)
|
2020-05-11 |
2021-11-18 |
Genentech, Inc. |
Complement component c1s inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
|
|
WO2021231204A1
(en)
|
2020-05-11 |
2021-11-18 |
Genentech, Inc. |
Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same
|
|
CN115605592A
(zh)
|
2020-05-11 |
2023-01-13 |
基因泰克公司（Us） |
用于治疗神经系统疾病的补体组分c1r抑制剂以及相关的组合物、系统和使用它们的方法
|
|
WO2021229036A1
(en)
|
2020-05-13 |
2021-11-18 |
F. Hoffmann-La Roche Ag |
Oligonucleotide agonists targeting progranulin
|
|
EP4150090A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
|
WO2021231685A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
|
EP4150086A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
|
WO2021231679A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
|
EP4150088A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
|
WO2021231680A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
|
|
WO2021231691A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
|
|
EP4150078A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
|
US20230193269A1
(en)
|
2020-05-22 |
2023-06-22 |
Boehringer Ingelheim International Gmbh |
Oligonucleotides for splice modulation of card9
|
|
US11408000B2
(en)
|
2020-06-03 |
2022-08-09 |
Triplet Therapeutics, Inc. |
Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
|
|
US20230212572A1
(en)
|
2020-06-09 |
2023-07-06 |
Roche Innovation Center Copenhagen A/S |
Guanosine Analogues for Use in Therapeutics Polynucleotides
|
|
AR122731A1
(es)
|
2020-06-26 |
2022-10-05 |
Hoffmann La Roche |
Oligonucleótidos mejorados para modular la expresión de fubp1
|
|
IL298530A
(en)
|
2020-06-29 |
2023-01-01 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating plp1
|
|
TW202219273A
(zh)
|
2020-07-23 |
2022-05-16 |
瑞士商赫孚孟拉羅股份公司 |
靶向ｒｎａ結合蛋白位點之寡核苷酸
|
|
WO2022018155A1
(en)
|
2020-07-23 |
2022-01-27 |
F. Hoffmann-La Roche Ag |
Lna oligonucleotides for splice modulation of stmn2
|
|
AU2021315992A1
(en)
|
2020-07-28 |
2023-02-09 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing app expression
|
|
CN111671913B
(zh)
*
|
2020-07-30 |
2022-02-08 |
四川大学 |
一种量子点-小核酸偶联物及其用途
|
|
KR20230048052A
(ko)
|
2020-08-07 |
2023-04-10 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Scn2a를 조절하는 화합물 및 방법
|
|
CN116157522A
(zh)
|
2020-08-21 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
A1cf抑制剂用于治疗乙型肝炎病毒感染的用途
|
|
WO2022072950A1
(en)
*
|
2020-10-02 |
2022-04-07 |
Sirnaomics, Inc. |
NUCLEOSIDE CONTAINING siRNAS FOR TREAT VIRAL DISEASES
|
|
MX2023005736A
(es)
|
2020-11-18 |
2023-05-25 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para modular la expresion de angiotensinogeno.
|
|
AR124227A1
(es)
|
2020-12-03 |
2023-03-01 |
Hoffmann La Roche |
Oligonucleótidos antisentido que actúan sobre atxn3
|
|
TW202237842A
(zh)
|
2020-12-03 |
2022-10-01 |
瑞士商赫孚孟拉羅股份公司 |
靶向ａｔｘｎ３之反義寡核苷酸
|
|
US12018261B2
(en)
|
2020-12-18 |
2024-06-25 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating factor XII
|
|
CN116583603A
(zh)
|
2020-12-18 |
2023-08-11 |
豪夫迈·罗氏有限公司 |
靶向颗粒蛋白前体的反义寡核苷酸
|
|
EP4267734A1
(en)
|
2020-12-22 |
2023-11-01 |
F. Hoffmann-La Roche AG |
Oligonucleotides targeting xbp1
|
|
CN114716518A
(zh)
*
|
2021-01-06 |
2022-07-08 |
圣诺制药公司 |
一种能够抑制pcsk9表达的分子构造及药物组合物
|
|
EP4284513A1
(en)
|
2021-01-26 |
2023-12-06 |
Universite Brest Bretagne Occidentale |
Novel stim1 splicing variants and uses thereof
|
|
TW202246500A
(zh)
|
2021-02-02 |
2022-12-01 |
瑞士商赫孚孟拉羅股份公司 |
用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸
|
|
WO2022189363A1
(en)
|
2021-03-08 |
2022-09-15 |
Les Laboratoires Servier |
Antisense oligonucleotides for inhibiting alpha-synuclein expression
|
|
WO2022232650A1
(en)
*
|
2021-04-30 |
2022-11-03 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing agt expression
|
|
EP4341405A1
(en)
|
2021-05-20 |
2024-03-27 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
|
KR20240019228A
(ko)
|
2021-06-08 |
2024-02-14 |
에프. 호프만-라 로슈 아게 |
올리고뉴클레오티드 프로그래눌린 효현제
|
|
US12378267B2
(en)
|
2021-06-17 |
2025-08-05 |
Entrada Therapeutics, Inc. |
Synthesis of FMOC-protected morpholino monomers and oligomers
|
|
EP4355759A1
(en)
|
2021-06-18 |
2024-04-24 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing ifnar1 expression
|
|
WO2022271786A1
(en)
|
2021-06-23 |
2022-12-29 |
University Of Massachusetts |
Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
|
|
EP4363574A1
(en)
|
2021-06-29 |
2024-05-08 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
|
WO2023034561A2
(en)
*
|
2021-09-02 |
2023-03-09 |
Vanderbilt University |
Lipophilic oligonucleotide conjugates
|
|
US11912779B2
(en)
|
2021-09-16 |
2024-02-27 |
Avidity Biosciences, Inc. |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
|
US20250352667A1
(en)
|
2021-10-22 |
2025-11-20 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
|
EP4426833A1
(en)
|
2021-11-03 |
2024-09-11 |
F. Hoffmann-La Roche AG |
Oligonucleotides for modulating apolipoprotein e4 expression
|
|
WO2023083906A2
(en)
|
2021-11-11 |
2023-05-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical combinations for treatment of hbv
|
|
WO2023102188A1
(en)
*
|
2021-12-03 |
2023-06-08 |
Quralis Corporation |
Gapmer antisense oligonucleotides with modified backbone chemistries
|
|
EP4444882A1
(en)
|
2021-12-07 |
2024-10-16 |
F. Hoffmann-La Roche AG |
Antisense oligonucleotides targeting actl6b
|
|
CN119095603A
(zh)
|
2021-12-17 |
2024-12-06 |
豪夫迈·罗氏有限公司 |
用于调节rtel1和fubp1的寡核苷酸的组合
|
|
CN118489009A
(zh)
|
2021-12-17 |
2024-08-13 |
豪夫迈·罗氏有限公司 |
寡核苷酸gba激动剂
|
|
CN118434860A
(zh)
|
2021-12-20 |
2024-08-02 |
豪夫迈·罗氏有限公司 |
苏糖核酸反义寡核苷酸及其方法
|
|
WO2023141507A1
(en)
|
2022-01-20 |
2023-07-27 |
Genentech, Inc. |
Antisense oligonucleotides for modulating tmem106b expression
|
|
US20240167040A1
(en)
|
2022-02-21 |
2024-05-23 |
Hoffmann-La Roche Inc. |
Antisense oligonucleotide
|
|
AU2023234185A1
(en)
|
2022-03-16 |
2024-10-03 |
Daiichi Sankyo Company, Limited |
siRNA FOR SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR-2
|
|
TW202400786A
(zh)
|
2022-03-16 |
2024-01-01 |
日商第一三共股份有限公司 |
具有RNAi活性的化學修飾寡核苷酸
|
|
WO2023217890A1
(en)
|
2022-05-10 |
2023-11-16 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting cfp-elk1 intergene region
|
|
EP4526445A1
(en)
|
2022-05-18 |
2025-03-26 |
F. Hoffmann-La Roche AG |
Improved oligonucleotides targeting rna binding protein sites
|
|
EP4282964A1
(en)
*
|
2022-05-23 |
2023-11-29 |
Universitat de Valéncia |
Oligonucleotides conjugated to oleic acid and uses thereof
|
|
JP2025520514A
(ja)
|
2022-06-17 |
2025-07-03 |
エフ． ホフマン－ラ ロシュ アーゲー |
プログラニュリンを標的とするためのアンチセンスオリゴヌクレオチド
|
|
EP4332221A1
(en)
|
2022-08-29 |
2024-03-06 |
Roche Innovation Center Copenhagen A/S |
Threose nucleic acid antisense oligonucleotides and methods thereof
|
|
KR20250059413A
(ko)
|
2022-09-06 |
2025-05-02 |
에프. 호프만-라 로슈 아게 |
눈에 투여하기 위한 이중 가닥 rna 분자
|
|
CN120239607A
(zh)
|
2022-09-23 |
2025-07-01 |
Ionis制药公司 |
用于降低mecp2表达的化合物和方法
|
|
WO2024112809A2
(en)
*
|
2022-11-21 |
2024-05-30 |
Pepgen Inc. |
Cell-penetrating peptides, conjugates thereof, and methods of their use
|
|
WO2024126654A1
(en)
|
2022-12-14 |
2024-06-20 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting actl6b
|
|
EP4652273A1
(en)
|
2023-01-16 |
2025-11-26 |
Institut National de la Recherche pour l'Agriculture, l'Alimentation et l'Environnement |
Antisense molecules and their uses for the treatment of coronavirus infection, in particular the treatment of covid-19 related to sars-cov-2 infection
|
|
KR20250162631A
(ko)
|
2023-01-19 |
2025-11-18 |
알토스 랩스, 인크. |
장기 이식에서의 재생 인자의 용도
|
|
WO2024196893A1
(en)
*
|
2023-03-17 |
2024-09-26 |
Camford Labs Inc. |
Chemically modified nucleotides
|
|
WO2024199445A1
(en)
*
|
2023-03-30 |
2024-10-03 |
Ractigen Therapeutics |
Vehicles for delivering oligonucleotides and methods of use thereof
|
|
CN121263524A
(zh)
|
2023-05-04 |
2026-01-02 |
豪夫迈·罗氏有限公司 |
能够上调葡糖脑苷脂酶表达的寡核苷酸
|
|
TW202508607A
(zh)
*
|
2023-05-19 |
2025-03-01 |
大陸商北京炫景瑞醫藥科技有限公司 |
雙股寡核苷酸及其共軛物和用途
|
|
US20250034576A1
(en)
|
2023-06-16 |
2025-01-30 |
Hoffmann-La Roche Inc. |
Double Stranded Oligonucleotide For Modulating JAK1 Expression
|
|
WO2025036916A1
(en)
|
2023-08-16 |
2025-02-20 |
Les Laboratoires Servier |
Oligonucleotides for modulating kcnt1 expression
|
|
WO2026006436A1
(en)
|
2024-06-25 |
2026-01-02 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of tar dna binding protein 43 kda (tdp43)
|